BACKGROUND: Selumetinib (AZD6244, ARRY-142886) is a second generation MEK inhibitor that is currently in clinical trials for various solid malignancies. MEK kinase inhibitors are associated with dermatologic toxicities. While reactions affecting the skin, hair and nails to other targeted agents, such as epidermal growth factor receptor inhibitors (EGFRIs) have been abundantly described in recent years, the dermatologic toxicities associated with MEK inhibitors have not been well characterized. Similarly, their management may present a challenge in clinical trials. We reviewed the clinical presentation, evolution and management of dermatologic toxicities associated with selumetinib. METHODS: A retrospective review of medical records of 11 patients referred to the Dermatology Service with dermatologic toxicities secondary to selumetinib was performed. Data from two phase II trials in which selumetinib was used to treat advanced metastatic cutaneous, mucosal, or uveal melanomas were reviewed. Parameters studied included the time to onset, clinical presentation, histology and management. In addition, the clinical database was accessed to retrieve clinical photographs when available. RESULTS: Eight patients received selumetinib suspension orally at 100 mg twice a day and three patients received a newer capsule formulation at the maximum tolerated dose of 75 mg with the same frequency. The following adverse effects were observed: papulopustular rash (100%), xerosis (36%), pruritus (45%), fissures (9%), telangiectasias (27%), hyperpigmentation (9%), alopecia (9%), angular cheilitis (9%), and paronychia (9%). In addition, secondary bacterial infection with Staphylococcus aureus was documented in 3 patients (27%). CONCLUSIONS: Dermatologic side-effects associated with selumetinib were similar to those seen with epidermal growth factor receptor inhibitors (EGFRIs). Treatment approaches used for EGFRI-induced dermatologic reactions may be potentially utilized to manage those associated with selumetinib.
BACKGROUND:Selumetinib (AZD6244, ARRY-142886) is a second generation MEK inhibitor that is currently in clinical trials for various solid malignancies. MEK kinase inhibitors are associated with dermatologic toxicities. While reactions affecting the skin, hair and nails to other targeted agents, such as epidermal growth factor receptor inhibitors (EGFRIs) have been abundantly described in recent years, the dermatologic toxicities associated with MEK inhibitors have not been well characterized. Similarly, their management may present a challenge in clinical trials. We reviewed the clinical presentation, evolution and management of dermatologic toxicities associated with selumetinib. METHODS: A retrospective review of medical records of 11 patients referred to the Dermatology Service with dermatologic toxicities secondary to selumetinib was performed. Data from two phase II trials in which selumetinib was used to treat advanced metastatic cutaneous, mucosal, or uveal melanomas were reviewed. Parameters studied included the time to onset, clinical presentation, histology and management. In addition, the clinical database was accessed to retrieve clinical photographs when available. RESULTS: Eight patients received selumetinib suspension orally at 100 mg twice a day and three patients received a newer capsule formulation at the maximum tolerated dose of 75 mg with the same frequency. The following adverse effects were observed: papulopustular rash (100%), xerosis (36%), pruritus (45%), fissures (9%), telangiectasias (27%), hyperpigmentation (9%), alopecia (9%), angular cheilitis (9%), and paronychia (9%). In addition, secondary bacterial infection with Staphylococcus aureus was documented in 3 patients (27%). CONCLUSIONS: Dermatologic side-effects associated with selumetinib were similar to those seen with epidermal growth factor receptor inhibitors (EGFRIs). Treatment approaches used for EGFRI-induced dermatologic reactions may be potentially utilized to manage those associated with selumetinib.
Authors: Anna Liza C Agero; Stephen W Dusza; Cristiane Benvenuto-Andrade; Klaus J Busam; Patricia Myskowski; Allan C Halpern Journal: J Am Acad Dermatol Date: 2006-10 Impact factor: 11.527
Authors: Patricia M Lorusso; Alex A Adjei; Mary Varterasian; Shirish Gadgeel; Joel Reid; David Y Mitchell; Lorelei Hanson; Pamela DeLuca; Laura Bruzek; Jill Piens; Peggy Asbury; Keri Van Becelaere; Roman Herrera; Judith Sebolt-Leopold; Mark B Meyer Journal: J Clin Oncol Date: 2005-07-11 Impact factor: 44.544
Authors: Román Pérez-Soler; Jean Pierre Delord; Allan Halpern; Karen Kelly; James Krueger; Bartomeu Massutí Sureda; Joachim von Pawel; Jennifer Temel; Salvatore Siena; Denis Soulières; Leonard Saltz; James Leyden Journal: Oncologist Date: 2005-05
Authors: Tammie C Yeh; Vivienne Marsh; Bryan A Bernat; Josh Ballard; Heidi Colwell; Ron J Evans; Janet Parry; Darin Smith; Barbara J Brandhuber; Stefan Gross; Allison Marlow; Brian Hurley; Joe Lyssikatos; Patrice A Lee; James D Winkler; Kevin Koch; Eli Wallace Journal: Clin Cancer Res Date: 2007-03-01 Impact factor: 12.531
Authors: John Rinehart; Alex A Adjei; Patricia M Lorusso; David Waterhouse; J Randolph Hecht; Ronald B Natale; Oday Hamid; Mary Varterasian; Peggy Asbury; Eric P Kaldjian; Stephen Gulyas; David Y Mitchell; Roman Herrera; Judith S Sebolt-Leopold; Mark B Meyer Journal: J Clin Oncol Date: 2004-10-13 Impact factor: 44.544
Authors: Barry R Davies; Armelle Logie; Jennifer S McKay; Paul Martin; Samantha Steele; Richard Jenkins; Mark Cockerill; Sue Cartlidge; Paul D Smith Journal: Mol Cancer Ther Date: 2007-08 Impact factor: 6.261
Authors: Alex A Adjei; Roger B Cohen; Wilbur Franklin; Clive Morris; David Wilson; Julian R Molina; Lorelei J Hanson; Lia Gore; Laura Chow; Stephen Leong; Lara Maloney; Gilad Gordon; Heidi Simmons; Allison Marlow; Kevin Litwiler; Suzy Brown; Gregory Poch; Katie Kane; Jerry Haney; S Gail Eckhardt Journal: J Clin Oncol Date: 2008-04-07 Impact factor: 44.544
Authors: R Gutzmer; J C Hassel; K C Kähler; C Loquai; R Mössner; S Ugurel; L Zimmer; Für Komitee Kutane Nebenwirkungen Ado der das Ado Journal: Hautarzt Date: 2014-07 Impact factor: 0.751
Authors: Dong Joon Kim; Mee-Hyun Lee; Kanamata Reddy; Yani Li; Do Young Lim; Hua Xie; Sung-Young Lee; Young Il Yeom; Ann M Bode; Zigang Dong Journal: Carcinogenesis Date: 2013-01-25 Impact factor: 4.944
Authors: Alex A Adjei; Donald A Richards; Anthony El-Khoueiry; Fadi Braiteh; Carlos H R Becerra; Joe J Stephenson; Aram F Hezel; Morris Sherman; Lawrence Garbo; Diane P Leffingwell; Cory Iverson; Jeffrey N Miner; Zancong Shen; Li-Tain Yeh; Sonny Gunawan; David M Wilson; Kimberly J Manhard; Prabhu Rajagopalan; Heiko Krissel; Neil J Clendeninn Journal: Clin Cancer Res Date: 2015-12-07 Impact factor: 12.531